IPO

Synthetic.com’s publisher and editor, Simons Chase, interviews Matthew McKnight. Matt is the Chief Commercial Officer of Ginkgo Bioworks where he also leads the company’s biosecurity platform, Concentric by Ginkgo. Prior to Ginkgo, Matt spent 7 years as an investor at IndUS Growth Partners and was the President and COO of Decision Resources Group. He has … Read more

Immuneering Corp. applies translational bioinformatics to drug development. Its biopharmaceutical therapeutic focus is oncologic and neurologic diseases. The company has more than a decade of experience in translational bioinformatics that it believes allow it to generate superior insights into drug mechanisms of action and patient treatment responses. Immuneering has developed a disease-agnostic platform for human … Read more

Absci Corp describes itself as an AI-powered integrated drug creation platform. The company creates protein-based drugs (biologics) by unifying biologic drug discovery and cell line development into one process. This places Absci squarely under the umbrella of synthetic biology. The challenge in next-generation biologics is the linear steps needed to screen and select desired molecular … Read more

Caribou Biosciences is a clinical-stage biopharmaceutical company innovating in next-generation, genome-edited cell therapies. Its CRISPR hybrid RNA-DNA (chRDNA) guide technology has demonstrated superior specificity and high efficiency in preclinical studies, and, according to the company, has the potential to generate gene and cell therapies in oncology and in therapeutic areas beyond oncology, including immune cell … Read more

Zymergen, an Emeryville, California–based synthetic biotechnology firm, recently raised $500 million in an initial public offering (IPO) of stock on the NASDAQ exchange that values the 8-year-old company at over $3 billion. Four months ago, Zymergen launched its first product, Hyaline, a polymer film for electronic displays that it developed with Sumitomo Chemical. Zymergen makes … Read more

Ginkgo Bioworks, Inc.’s (“Ginkgo”) founders have been working together for nearly twenty years since they first met at MIT. They launched Ginkgo in 2008 with the consistent goal of developing a platform that makes cell programming easier for their customers and partners. Ginkgo’s platform leverages advanced robotic automation, proprietary software, and data analytics to continuously … Read more

Recursion Pharmaceuticals Inc. uses machine learning to hunt for new therapies. The company raised $436 million in an upsized initial public offering priced at the top of a marketed range. Last week , the Salt Lake City-based company sold about 24 million shares for $18 each. Recursion is among a crop of new startups called … Read more

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, and Arya Sciences Acquisition Corp III, a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors, announced in February a definitive business combination agreement. The combined company is expected to receive proceeds of approximately $350 million at the closing … Read more

Sensei Biotherapeutics, Inc., a Phase 2 biotech company based in Rockville, MD, is a developing bacteriophage-based platform for cancer therapies. In the first week of February, the company raised $133 million by offering 7 million shares at $19, above the range of $16 to $18. Sensei’s ImmunoPhage platform uses bacteriophage to induce an innate and … Read more